DISCOVERY TO CURE

DISCOVERY TO CURE was founded in early 2020 by entrepreneur and scientist Dr. Fuli Yu. It aims to advance the clinical application of TIL therapy for treating and curing solid tumor patients and improving their quality of life by seamlessly integrating multi-omics/bioinformatics/artificial intelligence with cell therapy. Since its establishment, DISCOVERY TO CURE has remained highly discreet, almost operating in "stealth mode" while quietly refining and developing its cutting-edge TIL (Tumor-Infiltrating Lymphocyte) treatment platform. Its current "arsenal" includes neoantigen-driven TIL, single-cell multi-omics TIL scanning, and end-to-end CMC. The company consistently adheres to a dual-driven strategy of independent research and external collaboration, having established close partnerships with numerous top-tier research institutions and teams in both China and the United States.